154 related articles for article (PubMed ID: 22418878)
1. Letter from the editor.
Ellis RW; Riedmann EM
Hum Vaccin Immunother; 2012 Mar; 8(3):281. PubMed ID: 22418878
[No Abstract] [Full Text] [Related]
2. Letter from the Editor.
Ellis R; Weiss A
Hum Vaccin Immunother; 2015; 11(6):1297. PubMed ID: 26086583
[No Abstract] [Full Text] [Related]
3. Questions for biotechs.
Bachmann M
Hum Vaccin; 2010 Jul; 6(7):527. PubMed ID: 20622523
[No Abstract] [Full Text] [Related]
4. Vaccines and adjuvants--special issue.
Robinson K; Oyston P
J Med Microbiol; 2012 Jul; 61(Pt 7):887-888. PubMed ID: 22538995
[No Abstract] [Full Text] [Related]
5. Questions for biotechs: AERAS.
Connolly J
Hum Vaccin; 2010 Dec; 6(12):962-3. PubMed ID: 21487239
[No Abstract] [Full Text] [Related]
6. Next generation personalized animals as an enabling technology in personalized vaccinology.
Poland GA; Mirochnitchenko O
Vaccine; 2013 Jan; 31(5):725-7. PubMed ID: 23337595
[No Abstract] [Full Text] [Related]
7. Letter from the editor.
Ellis R; Weiss A
Hum Vaccin Immunother; 2015; 11(5):1077. PubMed ID: 26018441
[No Abstract] [Full Text] [Related]
8. Vaccine Technology III: an ECI Conference held in Puerto Vallarta, Mexico from June 6-11, 2010.
Buckland BC; Aunins JG; Jansen K; Alves PM; Weiner D
Vaccine; 2011 Sep; 29(41):7115-6. PubMed ID: 21689708
[No Abstract] [Full Text] [Related]
9. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
10. Letter from the Editor.
Hum Vaccin Immunother; 2016; 12(1):1. PubMed ID: 26836324
[No Abstract] [Full Text] [Related]
11. Letter from the editor.
Ellis R; Weiss A
Hum Vaccin Immunother; 2015; 11(2):303. PubMed ID: 25826191
[No Abstract] [Full Text] [Related]
12. PharmaPlant: the new frontier in vaccines. Forward.
Buonaguro FM; Butler-Ransohoff JE
Expert Rev Vaccines; 2010 Aug; 9(8):805-7. PubMed ID: 20673004
[No Abstract] [Full Text] [Related]
13. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2014; 10(2):245-6. PubMed ID: 24836383
[No Abstract] [Full Text] [Related]
14. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2013 Apr; 9(4):721. PubMed ID: 24091588
[No Abstract] [Full Text] [Related]
15. Opportunities for vaccine research in Europe.
Gancberg D; Hoeveler A; Martini A; Draghia-Akli R
Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718
[No Abstract] [Full Text] [Related]
16. Vaccine adjuvants: insights from industry. Interview by Jenaid Rees.
Andréasson S
Expert Rev Vaccines; 2013 Jul; 12(7):731-2. PubMed ID: 23885818
[No Abstract] [Full Text] [Related]
17. Improved virus purification processes for vaccines and gene therapy.
Nestola P; Peixoto C; Silva RR; Alves PM; Mota JP; Carrondo MJ
Biotechnol Bioeng; 2015 May; 112(5):843-57. PubMed ID: 25677990
[TBL] [Abstract][Full Text] [Related]
18. Development translates discoveries into products.
Johnson M
Nat Biotechnol; 2008 Dec; 26(12):1385-6. PubMed ID: 19060877
[No Abstract] [Full Text] [Related]
19. A review on current downstream bio-processing technology of vaccine products.
Li M; Qiu YX
Vaccine; 2013 Feb; 31(9):1264-7. PubMed ID: 23313813
[TBL] [Abstract][Full Text] [Related]
20. New technologies for new influenza vaccines.
Shaw A
Vaccine; 2012 Jul; 30(33):4927-33. PubMed ID: 22579861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
